AtriCure, Inc. (NASDAQ:ATRC – Get Free Report) has been given an average rating of “Moderate Buy” by the twelve research firms that are presently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $52.00.
A number of brokerages have commented on ATRC. Zacks Research downgraded shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 24th. Piper Sandler lifted their price objective on shares of AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday, August 27th. Needham & Company LLC boosted their target price on shares of AtriCure from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Wednesday. Raymond James Financial set a $52.00 target price on AtriCure in a report on Tuesday, July 21st. Finally, UBS Group cut their price target on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th.
Read Our Latest Stock Report on AtriCure
AtriCure Price Performance
AtriCure (NASDAQ:ATRC – Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The business had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period in the previous year, the company posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Analysts anticipate that AtriCure will post 0.29 earnings per share for the current fiscal year.
Insider Activity
In other AtriCure news, Director Karen Prange sold 3,564 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total value of $138,283.20. Following the transaction, the director directly owned 22,809 shares in the company, valued at $884,989.20. This represents a 13.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Sven Wehrwein sold 25,000 shares of the company’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $37.84, for a total transaction of $946,000.00. Following the completion of the transaction, the director owned 40,518 shares of the company’s stock, valued at approximately $1,533,201.12. The trade was a 38.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 53,616 shares of company stock valued at $2,149,994 over the last 90 days. Insiders own 4.00% of the company’s stock.
Institutional Trading of AtriCure
A number of hedge funds and other institutional investors have recently made changes to their positions in ATRC. Bank of America Corp DE boosted its holdings in shares of AtriCure by 13.7% in the first quarter. Bank of America Corp DE now owns 768,561 shares of the medical device company’s stock valued at $21,927,000 after acquiring an additional 92,830 shares during the period. Assenagon Asset Management S.A. purchased a new stake in AtriCure in the 2nd quarter valued at $1,744,000. Rice Hall James & Associates LLC purchased a new stake in AtriCure in the 2nd quarter valued at $3,755,000. F m Investments LLC acquired a new stake in AtriCure during the 4th quarter worth $2,872,000. Finally, Vanguard Group Inc. boosted its stake in AtriCure by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock worth $193,993,000 after purchasing an additional 62,861 shares during the period. Institutional investors and hedge funds own 99.11% of the company’s stock.
About AtriCure
AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.
The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.
See Also
- Five stocks we like better than AtriCure
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.
